NASDAQ:PRPH ProPhase Labs (PRPH) Stock Price, News & Analysis $0.75 0.00 (0.00%) (As of 11/26/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About ProPhase Labs Stock (NASDAQ:PRPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ProPhase Labs alerts:Sign Up Key Stats Today's Range$0.71▼$0.7550-Day Range$0.74▼$2.6352-Week Range$0.66▼$7.48Volume92,682 shsAverage Volume61,177 shsMarket Capitalization$17.88 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingBuy Company OverviewProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Read More… This Crisis Could Be Worse Than 2008 (Ad)Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America is teetering on the edge of a collapse unlike anything we've seen.In my new book, "Midnight in America," I expose the hidden deals between Washington and Wall Street. ProPhase Labs Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks63rd Percentile Overall ScorePRPH MarketRank™: ProPhase Labs scored higher than 63% of companies evaluated by MarketBeat, and ranked 402nd out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingProPhase Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProPhase Labs has received no research coverage in the past 90 days.Read more about ProPhase Labs' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ProPhase Labs are expected to grow in the coming year, from ($1.23) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProPhase Labs is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProPhase Labs is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProPhase Labs has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.65% of the outstanding shares of ProPhase Labs have been sold short.Short Interest Ratio / Days to CoverProPhase Labs has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProPhase Labs has recently decreased by 25.23%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProPhase Labs does not currently pay a dividend.Dividend GrowthProPhase Labs does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.65% of the outstanding shares of ProPhase Labs have been sold short.Short Interest Ratio / Days to CoverProPhase Labs has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProPhase Labs has recently decreased by 25.23%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added ProPhase Labs to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ProPhase Labs insiders have not sold or bought any company stock.Percentage Held by Insiders20.70% of the stock of ProPhase Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.45% of the stock of ProPhase Labs is held by institutions.Read more about ProPhase Labs' insider trading history. Receive PRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address PRPH Stock News HeadlinesProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comProPhase Labs, Inc. Reports Financial Results and Strategic DevelopmentsProPhase Labs, Inc. (NASDAQ: PRPH) recently disclosed its financial performance for the quarter ending September 30, 2024, through a press release. In an announcement dated NovemNovember 16, 2024 | americanbankingnews.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 26, 2024 | WealthPress (Ad)ProPhase Labs, Inc. (PRPH) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | seekingalpha.comProPhase Labs: Strategic Moves for Future GrowthNovember 14, 2024 | markets.businessinsider.comProPhase Labs Announces Closing of Public Offering of Common StockNovember 13, 2024 | markets.businessinsider.comProPhase Labs Announces Proposed Public Offering of Common StockNovember 11, 2024 | theglobeandmail.comProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024November 11, 2024 | globenewswire.comSee More Headlines PRPH Stock Analysis - Frequently Asked Questions How have PRPH shares performed this year? ProPhase Labs' stock was trading at $4.52 at the start of the year. Since then, PRPH stock has decreased by 83.4% and is now trading at $0.7490. View the best growth stocks for 2024 here. How were ProPhase Labs' earnings last quarter? ProPhase Labs, Inc. (NASDAQ:PRPH) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.21. The company had revenue of $3.63 million for the quarter, compared to analysts' expectations of $9.86 million. ProPhase Labs had a negative trailing twelve-month return on equity of 62.92% and a negative net margin of 217.64%. Who are ProPhase Labs' major shareholders? Top institutional investors of ProPhase Labs include HighTower Advisors LLC (0.75%) and Geode Capital Management LLC (0.67%). View institutional ownership trends. How do I buy shares of ProPhase Labs? Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ProPhase Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Meta Platforms (META), Pfizer (PFE), Palantir Technologies (PLTR), Valero Energy (VLO), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX) and Energy Transfer (ET). Company Calendar Last Earnings5/09/2024Today11/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRPH CUSIPN/A CIK868278 Webwww.prophaselabs.com Phone(215) 345-0919Fax215-345-5920Employees130Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+1,368.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,780,000.00 Net Margins-217.64% Pretax Margin-298.21% Return on Equity-62.92% Return on Assets-30.22% Debt Debt-to-Equity Ratio0.48 Current Ratio1.47 Quick Ratio1.33 Sales & Book Value Annual Sales$12.75 million Price / Sales1.40 Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / Book0.27Miscellaneous Outstanding Shares23,874,000Free Float18,932,000Market Cap$17.88 million OptionableOptionable Beta-0.10 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:PRPH) was last updated on 11/26/2024 by MarketBeat.com Staff From Our PartnersA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | Sponsored140% Yields From Stocks Like Tesla? Here's How (Black Friday Special)140% Dividends from stocks like Tesla? Discover How for Just $9! For Black Friday, get the full details of ...Investors Alley | Sponsored9 hidden AI stocks set to thrive in Trump’s new eraAI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be wor...StockEarnings | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.